# [Retracted] EGFR/HER2 inhibitors effectively reduce the malignant potential of MDR breast cancer evoked by P-gp substrates in vitro and in vivo

**Authors:** Yiting Jin, Wei Zhang, Hongying Wang, Zijing Zhang, Chengyu Chu, Xiuping Liu, Qiang Zou

PMC · DOI: 10.3892/or.2026.9066 · 2026-02-02

## Full-text entities

- **Genes:** ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, PGP (phosphoglycolate phosphatase) [NCBI Gene 283871] {aka AUM, G3PP, PGPase}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}
- **Diseases:** breast cancer (MESH:D001943)
- **Chemicals:** Epirubicin (MESH:D015251), Trastuzumab (MESH:D000068878), Paxitaxel (-), Lapatinib (MESH:D000077341)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]

---
Source: https://tomesphere.com/paper/PMC12891925